AUROPHARMA: Q2 revenue reached ₹102,632.9 million as Lannett entered the consolidated results

What happened

Aurobindo Pharma reported consolidated Q2 revenue of ₹102,632.9 million and profit after tax of ₹11,238.4 million. Lannett was included in the consolidated results from June 29, making comparisons with prior periods less direct. The Board declared an interim dividend of ₹7 per share.

Confirmed

Global impact / market context

Including Lannett means the reported figures combine Aurobindo Pharma’s results with Lannett’s for part of the period, so changes from earlier periods may not show underlying business growth clearly. The ₹7 dividend also represents a cash distribution to shareholders, although its total cost is not provided.

Analyst inference

The figures provide a snapshot of revenue and profit, but the article gives no prior-period figures, forecasts, or segment breakdown. Investors therefore cannot tell from this information alone how much of the results reflects existing operations versus Lannett’s inclusion.

Analyst inference

What to watch

1. Look for the length of time Lannett is included in later reporting periods and for explanations that make comparisons with earlier results more informative. Analyst inference
2. Watch for further details on revenue and profit by business or geography; none are provided here to show which operations contributed to Q2 results. Analyst inference
3. Check whether the declared ₹7 per-share interim dividend is followed by details on payment timing and eligibility, which are not stated in the supplied article. Analyst inference

Evidence

• Original source link unavailable